In situ Breast Cancer



Breast carcinoma in situ (BCIS) is the penultimate step in the progression of normal epithelium from hyperplasia to invasive breast cancer. There are two types of BCIS: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Most BCIS of both types originate in the terminal duct lobular unit, with the type of cells and their growth pattern providing the distinguishing features. DCIS is a proliferation of presumably malignant epithelial cells confined to the mammary ducts and lobules without demonstrable evidence of invasion through the basement membrane into the surrounding stroma (Harris et al. 1997). DCIS is typically detected by mammography, as it is frequently associated with microcalcifications (Damiani et al. 2002). LCIS is a solid proliferation of generally small and often loosely cohesive cells with small, uniform, round to oval nuclei (Harris et al. 1997). The overall lobular architecture is maintained and the cells are contained within the basement membrane. LCIS is often multicentric and bilateral and is most commonly diagnosed incidentally by a breast procedure performed for another reason (Damiani et al. 2002).


Breast Cancer Breast Cancer Risk Invasive Breast Cancer Benign Breast Disease Postmenopausal Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ (2001) Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115:85–98PubMedCrossRefGoogle Scholar
  2. Adem C, Reynolds C, Soderberg CL et al (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1–11PubMedCrossRefGoogle Scholar
  3. Alpers CE, Wellings SR (1985) The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 16:796–807PubMedCrossRefGoogle Scholar
  4. Barchielli A, Paci E, Giorgi D (1999) Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. Cancer Causes Control 10:313–317PubMedCrossRefGoogle Scholar
  5. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239:1863–1867PubMedCrossRefGoogle Scholar
  6. Bijker N, Peterse JL, Duchateau L et al (2001) Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539–544PubMedCrossRefGoogle Scholar
  7. Boyages J, Delaney G, Taylor R (1999) Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 85:616–628PubMedCrossRefGoogle Scholar
  8. Boyd NF, Jensen HM, Cooke G, Han HL (1992) Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 84:1170–1179PubMedCrossRefGoogle Scholar
  9. Boyd NF, Rommens JM, Vogt K et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808PubMedCrossRefGoogle Scholar
  10. Brinton LA, Daling JR, Liff JM et al (1995) Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87:827–835PubMedCrossRefGoogle Scholar
  11. Brinton LA, Hoover R, Fraumeni JF Jr (1983) Epidemiology of minimal breast cancer. JAMA 249:483–487PubMedCrossRefGoogle Scholar
  12. Brinton LA, Hoover R, Fraumeni JF Jr (1986) Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 54:825–832PubMedGoogle Scholar
  13. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430–1441PubMedCrossRefGoogle Scholar
  14. Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541PubMedCrossRefGoogle Scholar
  15. Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964–969PubMedCrossRefGoogle Scholar
  16. Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93:1811–1817PubMedCrossRefGoogle Scholar
  17. Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Br Cancer Res Treat 78:7–15CrossRefGoogle Scholar
  18. Claus EB, Stowe M, Carter D (2003) Oral contraceptives and the risk of ductal breast carcinoma in situ. Br Cancer Res Treat 81:129–136CrossRefGoogle Scholar
  19. Colditz GA (2007) Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Br Cancer Res 9:108CrossRefGoogle Scholar
  20. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87:1234–1245CrossRefGoogle Scholar
  21. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  22. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727CrossRefGoogle Scholar
  23. Collins LC, Connolly JL, Page DL et al (2004) Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol 28:126–131PubMedCrossRefGoogle Scholar
  24. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 103:1778–1784PubMedCrossRefGoogle Scholar
  25. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B et al (2001) Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37:2365–2372PubMedCrossRefGoogle Scholar
  26. Dallal CM, Sullivan-Halley J, Ross RK et al (2007) Long-term recreational physical activity and risk of invasive and in situ breast cancer: the California teachers study. Arch Intern Med 167:408–415PubMedCrossRefGoogle Scholar
  27. Damiani S, Eusebi V (2002) Gross and microscopic pathology. In: Donegan WL, Spratt JS, eds. Cancer of the breast, 5th edn. Saunders, Philadelphia, pp 347–375Google Scholar
  28. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRefGoogle Scholar
  29. Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616Google Scholar
  30. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913–918PubMedCrossRefGoogle Scholar
  31. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958PubMedCrossRefGoogle Scholar
  32. Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr: 151–156Google Scholar
  33. Eusebi V, Feudale E, Foschini MP et al (1994) Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11:223–235PubMedGoogle Scholar
  34. Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE (2003) Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 12:161–164PubMedGoogle Scholar
  35. Fisher B, Costantino J, Redmond C et al (1993) Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581–1586PubMedCrossRefGoogle Scholar
  36. Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMedGoogle Scholar
  37. Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000PubMedCrossRefGoogle Scholar
  38. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28:400–418PubMedCrossRefGoogle Scholar
  39. Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86:429–438PubMedCrossRefGoogle Scholar
  40. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 100:238–244PubMedCrossRefGoogle Scholar
  41. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B (1991) Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol 47:139–147PubMedCrossRefGoogle Scholar
  42. Friedenreich CM (2001) Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10:15–32PubMedCrossRefGoogle Scholar
  43. Gammon MD, Santella RM, Neugut AI et al (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677–685PubMedGoogle Scholar
  44. Gammon MD, Schoenberg JB, Teitelbaum SL et al (1998) Cigarette smoking and breast cancer risk among young women (United States). Cancer Causes Control 9:583–590PubMedCrossRefGoogle Scholar
  45. Gammon MD, Wolff MS, Neugut AI et al (2002) Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev 11:686–697PubMedGoogle Scholar
  46. Gandini S, Merzenich H, Robertson C, Boyle P (2000) Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 36:636–646PubMedCrossRefGoogle Scholar
  47. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281:2091–2097PubMedCrossRefGoogle Scholar
  48. Gill JK, Maskarinec G, Pagano I, Kolonel LN (2006) The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Br Cancer Res 8:R30CrossRefGoogle Scholar
  49. Gill JK, Press MF, Patel AV, Bernstein L (2006) Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 17:1155–1162PubMedCrossRefGoogle Scholar
  50. Goldschmidt RA, Victor TA (1996) Lobular carcinoma in situ of the breast. Semin Surg Oncol 12:314–320PubMedCrossRefGoogle Scholar
  51. Gorski B, Narod SA, Lubinski J (2005) A common missense variant in BRCA2 predisposes to early onset breast cancer. Br Cancer Res 7:R1023–R1027CrossRefGoogle Scholar
  52. Haagenson C (1986) Lobular neoplasia (lobular carcinoma in situ). In: Haagenson C (ed) Diseases of the breast. Saunders, PhiladelphiaGoogle Scholar
  53. Habel LA, Daling JR, Newcomb PA et al (1998) Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 7:689–696PubMedGoogle Scholar
  54. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS (1997) Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225:69–75PubMedCrossRefGoogle Scholar
  55. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Br Cancer Res 6:213–218CrossRefGoogle Scholar
  56. Hankinson SE, Hunter D (2002) Breast cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 301–339Google Scholar
  57. Harris J, Morrow M, Norton L (1997) Malignant tumors of the breast. In: Devita VT, Jr, Hellman S, Rosenberg SA (eds). Cancer principles & practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 1557–1616Google Scholar
  58. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51:1277–1283PubMedCrossRefGoogle Scholar
  59. Humphrey LL, Helfand M, Chan BK, Woolf SH (2002) Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:347–360PubMedGoogle Scholar
  60. Hunter DJ, Spiegelman D, Adami HO et al (1996) Cohort studies of fat intake and the risk of breast cancer – a pooled analysis. N Engl J Med 334:356–361PubMedCrossRefGoogle Scholar
  61. Hwang ES, Esserman LJ (1999) Management of ductal carcinoma in situ. Surg Clin North Am 79:1007–1030, viiiPubMedCrossRefGoogle Scholar
  62. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25:642–647PubMedCrossRefGoogle Scholar
  63. IARC (2002) IARC handbooks on cancer prevention, Vol. 6: weight control and physical activity. IARC Press, Lyon, FranceGoogle Scholar
  64. Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Br Cancer Res 8:R22Google Scholar
  65. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Br Cancer Res 9:R28CrossRefGoogle Scholar
  66. Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355:528–533PubMedCrossRefGoogle Scholar
  67. Kauff ND, Brogi E, Scheuer L et al (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97:1601–1608PubMedCrossRefGoogle Scholar
  68. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V (1997) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89:76–82PubMedGoogle Scholar
  69. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99:1335–1339PubMedCrossRefGoogle Scholar
  70. Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95:1692–1702PubMedGoogle Scholar
  71. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRefGoogle Scholar
  72. Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145PubMedCrossRefGoogle Scholar
  73. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO (1998) Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J Cancer 77:330–332PubMedCrossRefGoogle Scholar
  74. Lerwill MF (2004) Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 28:1076–1091PubMedCrossRefGoogle Scholar
  75. Levi F, Randimbison L, Te VC, La Vecchia C (2005) Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer 116:820–823PubMedCrossRefGoogle Scholar
  76. Levi F, Te VC, Randimbison L, La Vecchia C (1997) Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 33:903–906PubMedCrossRefGoogle Scholar
  77. Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773–2780PubMedCrossRefGoogle Scholar
  78. Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 106:2104–2112PubMedCrossRefGoogle Scholar
  79. Lipworth L, Bailey LR, Trichopoulos D (2000) History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. J Natl Cancer Inst 92:302–312PubMedCrossRefGoogle Scholar
  80. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5:961–965PubMedGoogle Scholar
  81. Luke C, Priest K, Roder D (2006) Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening. Asian Pac J Cancer Prev 7:69–74PubMedGoogle Scholar
  82. MacKenzie TA, Titus-Ernstoff L, Vacek PM et al (2007) Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control 18:939–945PubMedCrossRefGoogle Scholar
  83. McCarthy EP, Burns RB, Freund KM et al (2000) Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 48:1226–1233PubMedGoogle Scholar
  84. McTiernan A (2003) Behavioral risk factors in breast cancer: can risk be modified? Oncologist 8:326–334PubMedCrossRefGoogle Scholar
  85. Meeske K, Press M, Patel A, Bernstein L (2004) Impact of reproductive factors and lactation on breast carcinoma in situ risk. Int J Cancer 110:102–109PubMedCrossRefGoogle Scholar
  86. Millikan R, Eaton A, Worley K et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Br Cancer Res Treat 79:355–364CrossRefGoogle Scholar
  87. Millikan RC, Player J, de Cotret AR et al (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Br Cancer Res 6:R264–R274CrossRefGoogle Scholar
  88. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856–1865PubMedCrossRefGoogle Scholar
  89. Mohsin SK O‘Connell P, Allred DC, Libby AL (2005) Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Br Cancer Res Treat 90:249–256CrossRefGoogle Scholar
  90. Mommers EC, Leonhart AM, Falix F et al (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194:327–333PubMedCrossRefGoogle Scholar
  91. Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ (2001) Nuclear cytometric changes in breast carcinogenesis. J Pathol 193:33–39PubMedCrossRefGoogle Scholar
  92. Nasca PC, Liu S, Baptiste MS, Kwon CS, Jacobson H, Metzger BB (1994) Alcohol consumption and breast cancer: estrogen receptor status and histology. Am J Epidemiol 140:980–988PubMedGoogle Scholar
  93. National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V.2.2007. Available at 2007
  94. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2007) Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2262–2268PubMedCrossRefGoogle Scholar
  95. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA (1987) Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 56:814–819PubMedGoogle Scholar
  96. Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49:751–758PubMedCrossRefGoogle Scholar
  97. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232–1239PubMedCrossRefGoogle Scholar
  98. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361:125–129PubMedCrossRefGoogle Scholar
  99. Patel AV, Press MF, Meeske K, Calle EE, Bernstein L (2003) Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer 98:2161–2169PubMedCrossRefGoogle Scholar
  100. Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949PubMedCrossRefGoogle Scholar
  101. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17–35PubMedGoogle Scholar
  102. Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773–1783PubMedCrossRefGoogle Scholar
  103. Posner MC, Wolmark N (1992) Non-invasive breast carcinoma. Br Cancer Res Treat 21:155–164CrossRefGoogle Scholar
  104. Potischman N, Coates RJ, Swanson CA et al (2002) Increased risk of early-stage breast cancer related to consumption of sweet foods among women less than age 45 in the United States. Cancer Causes Control 13:937–946PubMedCrossRefGoogle Scholar
  105. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRefGoogle Scholar
  106. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7:910–918PubMedCrossRefGoogle Scholar
  107. Reinier KS, Vacek PM, Geller BM (2007) Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Br Cancer Res Treat 103:343–348CrossRefGoogle Scholar
  108. Rich-Edwards JW, Goldman MB, Willett WC et al (1994) Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 171:171–177PubMedGoogle Scholar
  109. Ries LAG, Melbert D, Krapcho M et al (2008) SEER cancer statistics review, 1975–2005. National Cancer Institute, Bethesda., based on November 2007 SEER data submission, posted to the SEER web siteGoogle Scholar
  110. Rosen P, Snyder RE, Foote FW, Wallace T (1970) Detection of occult carcinoma in the apparently benign breast biopsy through specimen radiography. Cancer 26:944–952PubMedCrossRefGoogle Scholar
  111. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332PubMedCrossRefGoogle Scholar
  112. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  113. Sasson AR, Fowble B, Hanlon AL et al (2001) Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 91:1862–1869PubMedCrossRefGoogle Scholar
  114. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN (1994) Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5:491–500PubMedCrossRefGoogle Scholar
  115. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491PubMedCrossRefGoogle Scholar
  116. Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321PubMedCrossRefGoogle Scholar
  117. Schnitt SJ, Morrow M (1999) Lobular carcinoma in situ: current concepts and controversies. Semin Diagn Pathol 16:209–223PubMedGoogle Scholar
  118. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI (2000) Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Cancer 88:946–954PubMedCrossRefGoogle Scholar
  119. Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45:277–282PubMedGoogle Scholar
  120. Solin LJ, Fourquet A, Vicini FA et al (2005) Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103:1137–1146PubMedCrossRefGoogle Scholar
  121. Solin LJ, Fourquet A, Vicini FA et al (2001) Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 50:991–1002PubMedCrossRefGoogle Scholar
  122. Sprague BL, Trentham-Dietz A, Garcia-Closas M et al (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680–1686PubMedCrossRefGoogle Scholar
  123. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM (2007) Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16:236–243PubMedCrossRefGoogle Scholar
  124. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274:137–142PubMedCrossRefGoogle Scholar
  125. Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657PubMedCrossRefGoogle Scholar
  126. Sun CC, Lenoir G, Lynch H, Narod SA (1996) In-situ breast cancer and BRCA1. Lancet 348:408PubMedCrossRefGoogle Scholar
  127. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 9 Regs Limited-Use, Nov 2007 Sub (1973–2005) – Linked to County Attributes – Total U.S., 1969–2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission (
  128. Swanson CA, Coates RJ, Schoenberg JB et al (1996) Body size and breast cancer risk among women under age 45 years. Am J Epidemiol 143:698–706PubMedGoogle Scholar
  129. Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531PubMedCrossRefGoogle Scholar
  130. Terry MB, Zhang FF, Kabat G et al (2006) Lifetime alcohol intake and breast cancer risk. Ann Epidemiol 16:230–240PubMedCrossRefGoogle Scholar
  131. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9:697–703PubMedGoogle Scholar
  132. Trentham-Dietz A, Nichols HB, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2007) Cigarette smoking and risk of breast carcinoma in situ. Epidemiology 18:629–638PubMedCrossRefGoogle Scholar
  133. Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH (2005) Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Br Cancer Res 7:R605–R608CrossRefGoogle Scholar
  134. Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 20:2736–2744PubMedCrossRefGoogle Scholar
  135. Warnberg F, Nordgren H, Bergkvist L, Holmberg L (2001) Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85:869–874PubMedCrossRefGoogle Scholar
  136. Warnberg F, Yuen J, Holmberg L (2000) Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355:724–725PubMedCrossRefGoogle Scholar
  137. Weiss HA, Brinton LA, Brogan D et al (1996) Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 73:1298–1305PubMedGoogle Scholar
  138. Welch HG, Black WC (1997) Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med 127:1023–1028PubMedGoogle Scholar
  139. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39:1746–1754PubMedCrossRefGoogle Scholar
  140. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds) (2001) SEER summary stage manual – 2000: codes and coding instructions. National Cancer Institute, Bethesda. NIH Pub. No. 01-4969Google Scholar
  141. Zagouri F, Sergentanis TN, Zografos GC (2007) Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol 5:57PubMedCrossRefGoogle Scholar
  142. Zeleniuch-Jacquotte A, Gu Y, Shore RE et al (2005) Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. Int J Cancer 114:323–327PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Population Health SciencesUniversity of Wisconsin-MadisonMadisonUSA
  2. 2.University of Wisconsin Paul P. Carbone Comprehensive Cancer CenterMadisonUSA

Personalised recommendations